MedCity News June 23, 2021
Regulatory T cells, or Tregs, have shown promise as a treatment for autoimmune diseases. Abata Therapeutics has raised $95 million in Series A financing for its Treg technology and CEO Samantha Singer said that multiple sclerosis is the startup’s first disease target.
Imagine an autoimmune disease treatment that activates only at the site of disease, shuts down inflammation from multiple sources, promotes tissue repair, and lasts for years. The source of this therapy, a type of immune cell, is already inside each and every one of us. Biotech startup Abata Therapeutics has raised $95 million to bring these cells to their full therapeutic potential for multiple sclerosis and other autoimmune conditions.
The Series A financing announced Wednesday was led by...